Revolution Medicines Quarterly Balance Sheets Chart
Quarterly
|
Annual
Revolution Medicines Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||
| cash and cash equivalents | 402,438,000 | 333,554,000 | 543,064,000 | 201,262,000 | 275,713,000 | 288,432,000 | 696,148,000 | 358,399,000 | 380,330,000 | 427,222,000 | 161,412,000 | 178,941,000 | 105,781,000 | 97,667,000 | 108,497,000 | 129,154,000 | 195,600,000 | 351,595,000 | 104,268,000 | 64,871,000 | 23,976,000 | 182,669,000 | 16,659,000 |
| marketable securities | 1,734,733,000 | 1,769,121,000 | 1,746,235,000 | 1,348,219,000 | 1,315,002,000 | 1,415,108,000 | 1,156,807,000 | 454,796,000 | 529,159,000 | 482,578,000 | 483,531,000 | 476,072,000 | 355,652,000 | 421,087,000 | 468,557,000 | 479,501,000 | 450,722,000 | 329,998,000 | 336,473,000 | 401,269,000 | 301,469,000 | 165,279,000 | 106,099,000 |
| prepaid expenses and other current assets | 39,268,000 | 31,907,000 | 38,333,000 | 29,658,000 | 34,015,000 | 25,662,000 | 25,072,000 | 10,963,000 | 10,093,000 | 8,958,000 | 10,569,000 | 15,155,000 | 15,989,000 | 10,206,000 | 6,790,000 | 7,469,000 | 8,162,000 | 8,248,000 | 6,988,000 | 7,459,000 | 7,605,000 | 5,688,000 | 2,486,000 |
| total current assets | 2,176,439,000 | 2,134,582,000 | 2,327,632,000 | 1,579,139,000 | 1,624,730,000 | 1,729,202,000 | 1,879,281,000 | 824,467,000 | 922,092,000 | 922,753,000 | 660,185,000 | 675,108,000 | 483,046,000 | 534,343,000 | 589,773,000 | 623,536,000 | 661,011,000 | 697,405,000 | 454,122,000 | 482,898,000 | 340,381,000 | 362,086,000 | 133,981,000 |
| property and equipment | 33,049,000 | 27,153,000 | 24,289,000 | 24,814,000 | 25,284,000 | 23,697,000 | 22,865,000 | 20,286,000 | 19,718,000 | 18,536,000 | 18,659,000 | 18,267,000 | 15,910,000 | 13,056,000 | 11,544,000 | 10,107,000 | 10,744,000 | 10,879,000 | 8,902,000 | 7,035,000 | 7,102,000 | 6,775,000 | 7,147,000 |
| operating lease right-of-use asset | 114,000,000 | 115,777,000 | 117,534,000 | 74,338,000 | 75,305,000 | 76,193,000 | 77,149,000 | 53,122,000 | 53,733,000 | 54,302,000 | 55,077,000 | 56,259,000 | 57,434,000 | 58,570,000 | 59,692,000 | 25,234,000 | 25,925,000 | 26,695,000 | 27,435,000 | 28,194,000 | 28,892,000 | 8,468,000 | |
| intangible assets | 56,136,000 | 56,403,000 | 56,670,000 | 56,937,000 | 57,205,000 | 57,472,000 | 57,739,000 | 58,006,000 | 58,273,000 | 58,540,000 | 58,807,000 | 59,075,000 | 59,342,000 | 59,609,000 | 59,876,000 | 60,143,000 | 60,410,000 | 60,678,000 | 60,945,000 | 61,212,000 | 61,479,000 | 61,746,000 | 62,013,000 |
| goodwill | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 | 14,608,000 |
| restricted cash | 3,916,000 | 3,698,000 | 3,698,000 | 2,888,000 | 3,031,000 | 3,031,000 | 3,031,000 | 2,391,000 | 2,594,000 | 1,737,000 | 1,737,000 | 1,737,000 | 1,737,000 | 1,737,000 | 1,737,000 | 1,084,000 | 1,084,000 | 1,084,000 | 1,084,000 | 1,084,000 | 1,084,000 | 214,000 | 214,000 |
| other noncurrent assets | 31,420,000 | 13,132,000 | 13,870,000 | 10,275,000 | 8,274,000 | 4,159,000 | 7,032,000 | 11,352,000 | 2,691,000 | 2,772,000 | 2,857,000 | 856,000 | 725,000 | 851,000 | 758,000 | 264,000 | 264,000 | 302,000 | 305,000 | 39,000 | 411,000 | 444,000 | 2,566,000 |
| total assets | 2,429,568,000 | 2,365,353,000 | 2,558,301,000 | 1,762,999,000 | 1,808,437,000 | 1,908,362,000 | 2,061,705,000 | 984,232,000 | 1,073,709,000 | 1,073,248,000 | 811,930,000 | 825,910,000 | 632,802,000 | 682,774,000 | 737,988,000 | 734,976,000 | 774,046,000 | 811,651,000 | 567,401,000 | 595,070,000 | 453,957,000 | 454,341,000 | 220,529,000 |
| liabilities and stockholdersʼ equity | |||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||
| accounts payable | 56,761,000 | 47,507,000 | 54,427,000 | 24,456,000 | 29,319,000 | 32,379,000 | 61,788,000 | 29,627,000 | 29,784,000 | 19,912,000 | 21,306,000 | 24,382,000 | 14,067,000 | 14,174,000 | 14,057,000 | 10,491,000 | 10,435,000 | 9,650,000 | 12,609,000 | 6,656,000 | 10,173,000 | 7,877,000 | 11,400,000 |
| accrued expenses and other current liabilities | 114,685,000 | 98,113,000 | 96,615,000 | 78,011,000 | 67,681,000 | 53,175,000 | 74,694,000 | 50,159,000 | 42,557,000 | 27,368,000 | 29,446,000 | 32,186,000 | 33,756,000 | 25,520,000 | 27,721,000 | 23,776,000 | 22,103,000 | 20,445,000 | 18,784,000 | 18,974,000 | 15,363,000 | 13,950,000 | 14,528,000 |
| operating lease liability, current | 13,088,000 | 12,979,000 | 12,872,000 | 8,396,000 | 8,332,000 | 8,169,000 | 7,369,000 | 5,755,000 | 5,718,000 | 5,921,000 | 6,773,000 | 7,017,000 | 6,030,000 | 6,331,000 | 4,959,000 | 4,926,000 | 3,700,000 | 3,645,000 | 3,619,000 | 3,285,000 | |||
| total current liabilities | 184,534,000 | 158,599,000 | 163,914,000 | 110,863,000 | 105,332,000 | 93,723,000 | 143,851,000 | 85,541,000 | 78,059,000 | 54,635,000 | 61,984,000 | 73,271,000 | 63,539,000 | 57,458,000 | 60,350,000 | 51,891,000 | 45,801,000 | 43,759,000 | 47,176,000 | 42,384,000 | 43,737,000 | 41,514,000 | 43,052,000 |
| deferred tax liability | 2,353,000 | 2,353,000 | 2,353,000 | 3,115,000 | 3,115,000 | 3,115,000 | 3,115,000 | 3,158,000 | 7,025,000 | 7,025,000 | 7,025,000 | 7,148,000 | 7,444,000 | 7,444,000 | 7,444,000 | 7,444,000 | 7,444,000 | 7,444,000 | 7,444,000 | 7,085,000 | 7,085,000 | 7,103,000 | 7,819,000 |
| operating lease liability, noncurrent | 119,699,000 | 121,363,000 | 122,971,000 | 78,310,000 | 79,079,000 | 79,860,000 | 80,575,000 | 57,093,000 | 57,538,000 | 57,676,000 | 57,432,000 | 58,183,000 | 58,922,000 | 59,583,000 | 26,827,000 | 27,566,000 | 28,294,000 | 29,669,000 | 30,337,000 | 7,403,000 | |||
| liability related to the sale of future royalties | 245,081,000 | ||||||||||||||||||||||
| warrant liability | 5,328,000 | 750,000 | 3,189,000 | 6,512,000 | |||||||||||||||||||
| other noncurrent liabilities | 7,204,000 | 4,138,000 | 670,000 | 1,644,000 | 656,000 | 3,040,000 | 1,458,000 | 982,000 | 252,000 | 1,694,000 | 301,000 | 471,000 | 219,000 | 1,634,000 | 634,000 | 932,000 | 608,000 | 1,439,000 | 632,000 | 1,089,000 | 691,000 | 589,000 | 655,000 |
| total liabilities | 564,199,000 | 287,203,000 | 293,097,000 | 196,695,000 | 189,589,000 | 182,895,000 | 235,511,000 | 146,774,000 | 142,874,000 | 121,030,000 | 126,742,000 | 144,491,000 | 133,961,000 | 131,781,000 | 135,420,000 | 96,772,000 | 89,040,000 | 89,071,000 | 92,725,000 | 90,000,000 | 93,459,000 | 69,025,000 | 67,994,000 |
| commitments and contingencies | |||||||||||||||||||||||
| stockholdersʼ equity: | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at june 30, 2025 and december 31, 2024, respectively; none issued and outstanding at june 30, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||
| common stock | 18,000 | 18,000 | 18,000 | 16,000 | 16,000 | 16,000 | 16,000 | 11,000 | 11,000 | 11,000 | 9,000 | 9,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 7,000 | 7,000 | 6,000 | 6,000 | |
| additional paid-in capital | 4,063,053,000 | 4,027,642,000 | 4,001,666,000 | 3,105,708,000 | 3,007,639,000 | 2,980,360,000 | 2,963,342,000 | 1,814,489,000 | 1,799,812,000 | 1,722,202,000 | 1,388,300,000 | 1,328,663,000 | 1,072,103,000 | 1,062,552,000 | 1,055,572,000 | 1,038,196,000 | 1,032,009,000 | 1,025,230,000 | 740,098,000 | 736,193,000 | 564,321,000 | 562,179,000 | 4,738,000 |
| accumulated other comprehensive income | 1,302,000 | 1,707,000 | 1,321,000 | 3,812,000 | -1,863,000 | -1,198,000 | 544,000 | -2,419,000 | -1,765,000 | -1,284,000 | -376,000 | -40,000 | 9,000 | 63,000 | 116,000 | 211,000 | 291,000 | 36,000 | 74,000 | ||||
| accumulated deficit | -2,199,004,000 | -1,951,217,000 | -1,737,801,000 | -1,543,232,000 | -1,386,944,000 | -1,253,711,000 | -1,137,708,000 | -976,171,000 | -867,737,000 | -769,439,000 | -701,341,000 | -644,834,000 | -571,505,000 | -510,283,000 | -452,636,000 | -399,960,000 | -347,020,000 | -302,721,000 | -265,545,000 | -231,341,000 | -204,120,000 | -157,386,000 | |
| total stockholdersʼ equity | 1,865,369,000 | 2,078,150,000 | 2,265,204,000 | 1,566,304,000 | 1,618,848,000 | ||||||||||||||||||
| total liabilities and stockholdersʼ equity | 2,429,568,000 | 2,365,353,000 | 2,558,301,000 | 1,762,999,000 | 1,808,437,000 | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at march 31, 2025 and december 31, 2024, respectively; none issued and outstanding at march 31, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||
| accounts receivable | 1,254,000 | 309,000 | 2,510,000 | 3,995,000 | 4,673,000 | 4,940,000 | 5,624,000 | 5,383,000 | 7,412,000 | 6,527,000 | 7,564,000 | ||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at december 31, 2024 and december 31, 2023, respectively; none issued and outstanding at december 31, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||
| warrant liabilities | 2,763,000 | 1,407,000 | 3,157,000 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at september 30, 2024 and december 31, 2023, respectively; none issued and outstanding at september 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at june 30, 2024 and december 31, 2023, respectively; none issued and outstanding at june 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||
| liabilities and stockholders' equity | |||||||||||||||||||||||
| stockholders' equity: | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at march 31, 2024 and december 31, 2023, respectively; none issued and outstanding at march 31, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||
| total stockholders' equity | 1,725,467,000 | 1,826,194,000 | 952,218,000 | 685,188,000 | 681,419,000 | 498,841,000 | 550,993,000 | 638,204,000 | 685,006,000 | 722,580,000 | 474,676,000 | 505,070,000 | 360,498,000 | 385,316,000 | |||||||||
| total liabilities and stockholders' equity | 1,908,362,000 | 2,061,705,000 | 1,073,248,000 | 811,930,000 | 825,910,000 | 632,802,000 | 682,774,000 | ||||||||||||||||
| deferred revenue, current | 1,434,000 | 4,459,000 | 9,686,000 | 9,686,000 | 11,433,000 | 12,358,000 | 12,665,000 | 8,337,000 | 9,964,000 | ||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at december 31, 2023 and december 31, 2022, respectively; none issued and outstanding at december 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||
| liabilities and stockholders’ equity | |||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at september 30, 2023 and december 31, 2022, respectively; zero shares issued and outstanding at september 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||
| accumulated other comprehensive loss | -871,000 | -1,251,000 | -556,000 | -1,780,000 | |||||||||||||||||||
| total stockholders’ equity | 837,458,000 | 930,835,000 | 602,568,000 | ||||||||||||||||||||
| total liabilities and stockholders’ equity | 984,232,000 | 1,073,709,000 | |||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at june 30, 2023 and december 31, 2022, respectively; zero shares issued and outstanding at june 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at march 31, 2023 and december 31, 2022, respectively; zero shares issued and outstanding at march 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||
| deferred revenue, noncurrent | 5,418,000 | 3,837,000 | 5,662,000 | 6,573,000 | 9,678,000 | 7,621,000 | 8,135,000 | ||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at december 31, 2022 and december 31, 2021, respectively; zero shares issued and outstanding at december 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at september 30, 2022 and december 31, 2021, respectively; zero shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at june 30, 2022 and december 31, 2021, respectively; zero shares issued and outstanding at june 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at march 31, 2022 and december 31, 2021, respectively; zero shares issued and outstanding at march 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||
| account receivable | 5,929,000 | ||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders' equity | |||||||||||||||||||||||
| operating lease liability | 6,214,000 | 3,672,000 | |||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 and zero shares authorized at december 31, 2021 and 2020, respectively; zero shares issued and outstanding at december 31, 2021 and 2020, respectively | |||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 737,988,000 | ||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at september 30, 2021 and december 31, 2020, respectively; zero shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders' equity | 734,976,000 | 774,046,000 | 811,651,000 | 567,401,000 | 595,070,000 | 453,957,000 | 454,341,000 | ||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at june 30, 2021 and december 31, 2020, respectively; zero shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||
| stockholders' equity | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized at march 31, 2021 and december 31, 2020, respectively; zero shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||
| receivable from related party | 6,393,000 | 9,299,000 | 7,331,000 | 8,450,000 | 8,737,000 | ||||||||||||||||||
| deferred revenue, related party, current | 12,111,000 | 13,109,000 | 14,582,000 | 16,402,000 | 17,124,000 | ||||||||||||||||||
| deferred rent, noncurrent | 1,741,000 | ||||||||||||||||||||||
| deferred revenue, related party, noncurrent | 8,481,000 | 9,773,000 | 11,609,000 | 12,416,000 | 14,727,000 | ||||||||||||||||||
| redeemable convertible preferred stock | 305,109,000 | ||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 and zero shares authorized at december 31, 2020 and 2019, respectively; zero shares issued and outstanding at december 31, 2020 and 2019, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 and zero shares authorized at september 30, 2020 and december 31, 2019, respectively; zero shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 and zero shares authorized at june 30, 2020 and december 31, 2019, respectively; zero shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 and zero shares authorized at march 31, 2020 and december 31, 2019, respectively; zero shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||
| accumulated | -176,905,000 | ||||||||||||||||||||||
| assets held for sale | |||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders' deficit | |||||||||||||||||||||||
| stockholders' (deficit) equity: | |||||||||||||||||||||||
| total stockholders' deficit | -152,574,000 | ||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders' deficit | 220,529,000 |
We provide you with 20 years of balance sheets for Revolution Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Revolution Medicines. Explore the full financial landscape of Revolution Medicines stock with our expertly curated balance sheets.
The information provided in this report about Revolution Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.